Downgrades: LLY, PPDI, PCL

This morning, Morgan Stanley initiated coverage on pharmaceutical giant Eli Lilly (LLY) with an U...  More »

This morning, Morgan Stanley initiated coverage on pharmaceutical giant Eli Lilly (LLY) with an Underweight rating. The firm sees drug patents expiring quickly with not enough new products in the pipeline to make up for the lost revenue.  « Less